AGC Inc.

FY25 net sales were JPY 2.0588 trillion, down JPY 8.8 billion YoY. Operating profit was JPY 127.5 billion, up JPY 1.6 billion YoY. Profit before tax was JPY 124.8 billion, up JPY 174.8 billion YoY. Profit attributable to owners of the parent improved significantly, and ROE improved to 4.7%. By segment, Architectural Glass sales rose to JPY 441.1 billion and OP to JPY 17.3 billion; Automotive sales rose to JPY 520.6 billion and OP to JPY 29.3 billion; Electronics sales fell to JPY 355.1 billion and OP to JPY 47.5 billion; Chemicals sales were JPY 584.2 billion and OP JPY 53 billion; Life Science sales were JPY 133.1 billion and operating loss was JPY 22.3 billion. FY25 operating cash flow was JPY 274.5 billion, investment cash flow was minus JPY 178.4 billion, and free cash flow was JPY 96.1 billion. CapEx was JPY 251.3 billion, depreciation JPY 179.8 billion, and R&D JPY 60.3 billion. Total assets were JPY 2.9501 trillion and the D/E ratio was 0.37. For FY26, management forecasts net sales of JPY 2.2 trillion, operating profit of JPY 150 billion, and ROE of 5.2%; CapEx is forecast at JPY 190 billion, depreciation JPY 183 billion, and R&D JPY 62 billion.

CEO Hirai said the company believes it has “hit the bottom” after several years of profit declines, but stressed that the real issue is achieving a full recovery and improving profitability more drastically. He framed the strategy around raising ROCE through stable production, productivity gains, disciplined pricing, higher-value products, tighter investment selection, lower inventory, and exits from businesses with weak growth potential. He also highlighted that electronics, automotive, architectural glass, integrated chemicals, and especially Life Science each have different turnaround paths, with Life Science and Essential Chemicals remaining the key challenges.

CFO Takegawa emphasized that FY25 results improved modestly at the operating level despite higher raw materials and fuel costs and weaker conditions in some businesses. He pointed to positive contributions from Automotive, pricing actions, product mix improvements, and earnings-improvement measures in Display, while noting negatives from lower PVC prices, fewer EUV mask blank shipments, and higher manufacturing and other costs. On the balance sheet and cash flow, he cited total assets of JPY 2.9501 trillion, D/E of 0.37, operating cash flow of JPY 274.5 billion, and FCF of JPY 96.1 billion. For FY26, he guided to JPY 2.2 trillion sales, JPY 150 billion operating profit, and JPY 190 billion CapEx, saying major capacity expansion investment was mostly completed in FY25.

Analysts focused on the turnaround timeline for Life Science and the structural issues in Essential Chemicals, asking whether AGC would consider deeper business reshaping. Management said Life Science could potentially return to ROCE of 15% to 20% once normal conditions return, but that meaningful recovery would likely take 1.5 to 2 years and full-year profitability in FY26 is unlikely; the Colorado site closure should stop the major bleeding, but the divestiture is still being negotiated. On Essential Chemicals, management said the market is likely at the bottom, but a true recovery will take time and depends partly on whether low-priced Chinese exports into Southeast Asia ease. Questions also probed whether the JPY 150 billion OP target is a commitment; Hirai said yes, while Shiokawa said downside risk is largely already factored in at this stage.